at Benzinga.com (Jan 12, 2015)
Arrowhead Research (ARWR -6.8%) says it's signed a research collaboration and license agreement with Shire (SHPG +0.8%) to develop and commercialize targeted peptide-drug conjugates by utilizing ARWR's human-derived Homing Peptide platform and SHPG's therapeutic payloads. Arrowhead will receive research funding and could be eligible for milestone payments of up to $32.8M for each development candidate, plus additional milestone payments for a second indication, as well as royalties on worldwide sales.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs